PHK
ARQT icon

Point72 Hong Kong’s Arcutis Biotherapeutics ARQT Stock Holding History

Point72 Hong Kong’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,280
Closed -$51.3K – 459
2025
Q1 		$51.3K Buy
+3,280
New +$46.2K ﹤0.01% 376
2022
Q3 		– Sell
-1,197
Closed -$26K – 1917
2022
Q2 		$26K Buy
1,197
+607
+103% +$12.5K ﹤0.01% 1501
2022
Q1 		$11K Buy
+590
New +$9.98K ﹤0.01% 1590
2021
Q3 		– Sell
-596
Closed -$16K – 1959
2021
Q2 		$16K Buy
+596
New +$16.8K ﹤0.01% 1667
2021
Q1 		– Sell
-176
Closed -$5K – 1788
2020
Q4 		$5K Buy
+176
New +$4.31K ﹤0.01% 1592

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Point72 Hong Kong's ARQT Position: Q2 2025 in Review

Point72 Hong Kong sold out of Arcutis Biotherapeutics (ARQT) in Q2 2025, closing a stake of 3,280 shares — an estimated $51.3K sold.

Point72 Hong Kong first reported a position in ARQT in Q4 2020 and held it in 5 quarters. The position peaked at $51.3K in Q1 2025. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

  • Point72 Hong Kong reported no remaining Arcutis Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 Hong Kong sold 3,280 Arcutis Biotherapeutics shares in Q2 2025, an estimated $51.3K.
  • Point72 Hong Kong first reported a position in Arcutis Biotherapeutics in Q4 2020 and held it in 5 quarters.
  • Point72 Hong Kong's Arcutis Biotherapeutics position peaked at $51.3K in Q1 2025.
  • 230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on Point72 Hong Kong's 13F filing for Q2 2025, filed 14 Aug 2025.